Equities research analysts predict that Accuray Incorporated (NASDAQ:ARAY) will post $111.45 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Accuray’s earnings, with estimates ranging from $110.70 million to $112.20 million. Accuray posted sales of $94.97 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 17.4%. The business is expected to issue its next earnings results after the market closes on Tuesday, August 22nd.

According to Zacks, analysts expect that Accuray will report full-year sales of $111.45 million for the current financial year, with estimates ranging from $382.00 million to $383.52 million. For the next fiscal year, analysts expect that the business will post sales of $401.28 million per share, with estimates ranging from $399.90 million to $402.65 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Accuray.

Accuray (NASDAQ:ARAY) last issued its earnings results on Thursday, April 27th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by $0.07. Accuray had a negative net margin of 8.61% and a negative return on equity of 61.49%. The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $110.23 million. During the same quarter in the previous year, the firm earned $0.01 earnings per share. The business’s quarterly revenue was down 7.6% compared to the same quarter last year.

A number of equities analysts recently commented on the company. Zacks Investment Research raised Accuray from a “strong sell” rating to a “hold” rating in a report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 target price on shares of Accuray in a report on Friday, June 30th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Accuray in a report on Sunday, April 30th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.04.

A number of large investors have recently bought and sold shares of ARAY. Norges Bank acquired a new stake in Accuray during the fourth quarter worth approximately $9,179,000. Neuberger Berman Group LLC boosted its stake in Accuray by 26.7% in the first quarter. Neuberger Berman Group LLC now owns 5,014,941 shares of the medical equipment provider’s stock worth $23,821,000 after buying an additional 1,057,654 shares in the last quarter. Vident Investment Advisory LLC boosted its stake in Accuray by 212.7% in the first quarter. Vident Investment Advisory LLC now owns 1,553,111 shares of the medical equipment provider’s stock worth $7,377,000 after buying an additional 1,056,395 shares in the last quarter. Bogle Investment Management L P DE acquired a new stake in Accuray during the first quarter worth approximately $1,952,000. Finally, Vanguard Group Inc. boosted its stake in Accuray by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock worth $30,623,000 after buying an additional 286,011 shares in the last quarter. 84.22% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $111.45 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/23/analysts-anticipate-accuray-incorporated-aray-will-announce-quarterly-sales-of-111-45-million.html.

Shares of Accuray (ARAY) opened at 4.45 on Friday. The company’s 50 day moving average price is $4.47 and its 200-day moving average price is $4.78. Accuray has a 1-year low of $3.85 and a 1-year high of $6.39. The company’s market capitalization is $369.35 million.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Get a free copy of the Zacks research report on Accuray (ARAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.